[8-K] bioAffinity Technologies, Inc. Reports Material Event

Rhea-AI Filing Summary

bioAffinity Technologies reported it will present new research at CHEST 2025, the annual meeting of the American College of Chest Physicians. The company’s project manager for product development, Rossella Titone, PhD, will present the poster titled “The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests.”

The presentation is scheduled for October 22, 2025 at 10:20 a.m. at poster board #4324. The company attached its press release and the full poster as Exhibits 99.1 and 99.2, which are incorporated by reference.

false 0001712762 0001712762 2025-10-20 2025-10-20 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2025-10-20 2025-10-20 0001712762 BIAF:WarrantsToPurchaseCommonStockMember 2025-10-20 2025-10-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2025

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41463		46-5211056
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.007 per share		BIAF		The Nasdaq Stock Market LLC (Nasdaq Capital Market)
Warrants to purchase Common Stock		BIAFW		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On October 20, 2025, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that it will present research at CHEST 2025, the annual meeting of the American College of Chest Physicians. Rossella Titone, PhD, the Company’s project manager for product development, will present the poster “The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests” on October 22, 2025, at 10:20 a.m. at poster board #4324.

Copies of the press release and poster are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release issued by bioAffinity Technologies, Inc., dated October 20, 2025
99.2		Poster entitled “The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests”
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 20, 2025	BIOAFFINITY TECHNOLOGIES, INC.
	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

-3-

FAQ

What did BIAF announce in this 8-K?

The company will present a research poster at CHEST 2025 and attached its press release (Exhibit 99.1) and the poster (Exhibit 99.2).

When is bioAffinity Technologies presenting at CHEST 2025?

The presentation is scheduled for October 22, 2025 at 10:20 a.m. at poster board #4324.

Who is presenting on behalf of BIAF?

Rossella Titone, PhD, project manager for product development, will present the poster.

What is the title of the poster?

“The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests.”

Does this 8-K include financial results or guidance for BIAF?

No. It describes a conference presentation and includes related exhibits.

Which exhibits were filed with the 8-K?

Exhibit 99.1 is the press release; Exhibit 99.2 is the research poster; Exhibit 104 is the cover page interactive data file.